BMY · Categories · Downgrades
BMY - Analyst downgrades
Bristol-Myers Squibb Company (BMY) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for BMY
- Bristol-Myers downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded Bristol-Myers from Outperform to Neutral and set a new price target of $42.00
- Bristol-Myers downgraded by Citigroup with a new price targetCitigroup downgraded Bristol-Myers from Buy to Neutral and set a new price target of $55.00 from $75.00 previously
- Bristol-Myers downgraded by Barclays with a new price targetBarclays downgraded Bristol-Myers from Overweight to Equal Weight and set a new price target of $41.00
- Bristol-Myers downgraded by Societe GeneraleSociete Generale downgraded Bristol-Myers from Buy to Hold
- Bristol-Myers downgraded by Redburn Atlantic with a new price targetRedburn Atlantic downgraded Bristol-Myers from Buy to Neutral and set a new price target of $54.00 from $77.00 previously
- Bristol-Myers downgraded by BofA Securities with a new price targetBofA Securities downgraded Bristol-Myers from Buy to Neutral and set a new price target of $60.00 from $68.00 previously
- Bristol-Myers downgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald downgraded Bristol-Myers from Overweight to Neutral and set a new price target of $55.00 from $68.00 previously
- Bristol-Myers downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded Bristol-Myers from Outperform to Neutral and set a new price target of $54.00 from $68.00 previously
- Bristol-Myers downgraded by BMO Capital Markets with a new price targetBMO Capital Markets downgraded Bristol-Myers from Outperform to Market Perform and set a new price target of $60.00
- Bristol-Myers downgraded by William BlairWilliam Blair downgraded Bristol-Myers from Outperform to Mkt Perform
- Bristol-Myers downgraded by GuggenheimGuggenheim downgraded Bristol-Myers from Buy to Neutral
- Bristol-Myers downgraded by Berenberg with a new price targetBerenberg downgraded Bristol-Myers from Buy to Hold and set a new price target of $76.00 from $82.00 previously
- Bristol-Myers downgraded by Raymond JamesRaymond James downgraded Bristol-Myers from Outperform to Mkt Perform
- Bristol-Myers downgraded by ArgusArgus downgraded Bristol-Myers from Buy to Hold
- Bristol-Myers Squibb downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Bristol-Myers Squibb from Overweight to Equal-Weight and set a new price target of $62.00